Globus Medical (GMED) Q1 2026 Earnings Transcript

Globus Medical reported Q1 revenue of $759.9 million, up 27% year over year, with adjusted EPS of $1.12, up 64.7%, and adjusted gross margin expanding to 69.2% from 67.3%. Management raised full-year 2026 non-GAAP EPS guidance to $4.70-$4.80 from $4.40-$4.50 while reaffirming revenue of $3.18 billion-$3.22 billion, citing margin gains and synergies but also cautioning that Nevro revenue may worsen before improving. The company also highlighted $110 million of buybacks in 2025, $390 million of remaining authorization, and new FDA 510(k) clearances for patient-specific lumbar products.

Analysis

The key signal is not the headline EPS beat; it is that GMED is converting scale into operating leverage while preserving pricing power in a category where competitors are increasingly forced to spend on rep recruitment, capital deployments, and software refreshes. That combination matters because it turns the company’s installed base into a self-funding distribution engine: every incremental procedure lowers the effective cost of the field force and increases recurring pull-through, which should keep margins rising even if procedure growth normalizes.

The more interesting second-order effect is the Enabling Technologies mix shift. Moving from upfront capital sales to lease/rental structures will suppress reported revenue near term, but it likely expands the addressable hospital set and embeds the platform more deeply in customer workflows. That can create a longer-duration annuity stream, but it also means the market may underwrite a revenue deceleration in the next 1-2 quarters before the economics show up in procedure volume and consumables.

Nevro remains the swing factor for sentiment, but the real issue is not just revenue volatility; it is management bandwidth and the risk that restructuring noise obscures underlying base-business momentum. If Nevro deteriorates another quarter or two, investors may temporarily overdiscount the entire story despite the fact that core spine, trauma, and robotics are still compounding. The setup suggests a good business with a messy acquisition overlay, which often creates a better entry than the numbers alone imply.

Contrarian view: the market may be too focused on the revenue guide being held flat and not enough on the durability of margin expansion. If cost actions continue and the company keeps winning share at roughly 3%-3.5% industry growth, EPS can compound faster than top line for several quarters. The main reversal risk is competitive intensity lengthening sales cycles enough to delay robot conversions and cross-sell, which would make the lease shift look like demand weakness instead of channel innovation.

Key Decisions for Investors

• Long GMED on 3-6 month horizon: use post-earnings consolidation as entry; target upside from multiple expansion if the market re-rates recurring-margin durability. Risk/reward is attractive because the base business is still comping well above market growth, while downside is buffered by cash generation and buybacks.
• Pair trade: long GMED / short MDT for 1-2 quarters. Thesis: GMED is taking share and monetizing workflow integration while MDT faces the more direct competitive pressure from installed-base displacement; risk is a broad orthopedics rerating that lifts both.
• Buy GMED Jan-2027 call spreads, struck around current spot to +20%. This expresses a view that EPS compounds faster than the stock reflects as gross margin and operating leverage flow through, while limiting premium if Nevro drags the narrative longer than expected.
• If already long, hedge with a tactical trim into strength if the stock begins pricing in uninterrupted top-line acceleration. The first place this story can miss is revenue optics, not earnings, so any multiple expansion should be paired with discipline on position size.